Precigen, Inc. Common Stock
$7.78
-$0.09 (-1.14%)
$7.70Day Range$8.04
Key Statistics
Market Cap
$2.79B
Shares Outstanding
358.0M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Aug 8, 2013
Round Lot
100
Locale
US
Trading Data
Day Open
$7.98
Day High
$8.04
Day Low
$7.70
Volume
9.58M
VWAP
$7.79
Prev Close
$7.87
Transactions
--
Acc. Volume
--
About Precigen, Inc. Common Stock
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
PHARMACEUTICAL PREPARATIONSSIC 283447 employees20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD, 20876301-556-9900IPO Aug 8, 2013US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001356090
- Composite FIGI
- BBG000QL8VH9
- Share Class FIGI
- BBG001SSB3T5
- Ticker Root
- PGEN
- SIC Code
- 2834
About Precigen, Inc. Common Stock (PGEN) Stock
Precigen, Inc. Common Stock (PGEN) closed the 2026-09-18 session at $7.78, down 1.14% versus the previous close (-0.09). The stock opened at $7.98 and traded between $7.70 and $8.04 during that session. Session trading volume was 9.6M shares. The volume-weighted average price (VWAP) is $7.79.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
Precigen, Inc. Common Stock has a market capitalization of $2.79 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. PGEN is listed on the XNAS exchange. The company employs approximately 47 people. Precigen, Inc. Common Stock is headquartered in GERMANTOWN, MD. The recorded listing date is 2013-08-08.
On this page you can find market PGEN stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.